000K utf8 1100 $c2021 1500 eng 2050 urn:nbn:de:gbv:8:3-2022-00251-4 2051 10.3390/biomedicines9101350 3000 Günther, Veronika 3010 Alkatout, Ibrahim 3010 Görg, Siegfried 3010 Maass, Nicolai Henning 3010 Meyerholz, Lisa 3010 von Otte, Sören 3010 Ziemann, Malte 4000 Live Birth Rates after Active Immunization with Partner Lymphocytes [Günther, Veronika] 4209 Although many potential causes have been established for recurrent implantation failure (RIF) and recurrent miscarriage (RM), about 50% of these remain idiopathic. Scientific research is focused on immunological risk factors. In the present study, we aim to evaluate live birth rates after immunization with paternal lymphocytes (lymphocyte immunotherapy (LIT)). This retrospective study consisted of 148 couples with a history of RM and/or RIF. The women underwent immunization with lymphocytes of their respective partners from November 2017 to August 2019. Fifty-five patients (43%) had live births. Stratified by indication (RM, RIF, combined), live birth rates in the RM and the combined group were significantly higher than that in the RIF group (53%, 59% and 33%, respectively, p = 0.02). The difference was especially noticeable during the first 90 days after immunization (conception rate leading to live births: 31%, 23% and 8% for RM, the combined group and RIF, respectively; p = 0.005), while there was no difference between groups during the later follow-up. LIT was associated with high live birth rates, especially in women with recurrent miscarriage. In view of the limited data from randomized studies, LIT cannot be recommended as routine therapy. However, it may be considered in individual cases. 4950 https://doi.org/10.3390/biomedicines9101350$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2022-00251-4$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/macau_mods_00002670 5051 610 5550 Immunization 5550 Implantation Failure 5550 Live Birth Rate 5550 Paternal Lymphocytes 5550 Recurrent Miscarriage